Diarrhea in patients with AIDS

Current Treatment Options in Gastroenterology

Volumn 9, Issue 1, 2006, Pages 23-37

  Morpeth, Susan C ^a   Thielman, Nathan M ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALCOHOL; ALPHA TOCOPHEROL; ANTIARRHYTHMIC AGENT; ASCORBIC ACID; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450 3A4; ERYTHROMYCIN; LOPINAVIR; METHOTREXATE; METRONIDAZOLE; NELFINAVIR; NITAZOXANIDE; PAROMOMYCIN; PHENYTOIN; POTASSIUM; RITONAVIR; SAQUINAVIR; SELENIUM; THEOPHYLLINE; TINIDAZOLE; UNINDEXED DRUG; VANCOMYCIN; VITAMIN B GROUP; WARFARIN; ZINC;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AIDS RELATED COMPLEX; ANAPHYLAXIS; ANOREXIA; ARTHROPATHY; BACTERIAL VIRULENCE; BONE MARROW SUPPRESSION; CHILDHOOD DISEASE; CHRONIC DIARRHEA; CLINICAL FEATURE; COLONOSCOPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRYSTALLURIA; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DUODENOSCOPY; DYSURIA; ELECTROLYTE INTAKE; EOSINOPHILIA; FECES CULTURE; FOOD HANDLING; GALLBLADDER DISEASE; GASTROENTERITIS; HAND WASHING; HEALTH HAZARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY DYSFUNCTION; LACTOSE INTOLERANCE; LEUKOPENIA; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALNUTRITION; MORTALITY; NAUSEA AND VOMITING; NEUTROPENIA; ORAL REHYDRATION THERAPY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PHOTOTOXICITY; PREGNANCY; PROTEINURIA; QT PROLONGATION; RAW FOOD; REVIEW; RISK ASSESSMENT; SALMONELLOSIS; SEIZURE; SIGMOIDOSCOPY; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMACH BIOPSY; TASTE DISORDER; TENDINITIS; THROMBOCYTOSIS; VITAMIN SUPPLEMENTATION;

EID: 33645466081     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0021-8     Document Type: Review

References (74)

1. Tramarin A, Parise N, Campostrini S, et al.: Association between diarrhea and quality of life in HIV-infected patients receiving highly active antiretroviral therapy. Qual Life Res 2004, 13:243-250.
2. Weber R, Ledergerber B, Zbinden R, et al.: Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Arch Intern Med 1999, 159:1473-1480.
3. Brink AK, Mahe C, Watera C, et al.: Diarrhea, CD4 counts and enteric infections in a community-based cohort of HIV-infected adults in Uganda. J Infect 2002, 45:99-106.
4. Ole-Nguyaine S, Crump J, Kibiki G, et al.: HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. Ann Trop Med Parasitol 2004, 98:171-179.
5. Groenewald P, Nannan N, Bourne D, et al.: Identifying deaths from AIDS in South Africa. AIDS 2005, 19:193-201.
6. Trout H, Mentre F, Panhard X, et al.: Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome. Antimicrob Agents Chemother 2004, 48:538-545.
7. Gurumurthy P, Ramachandran G, Hemanth Kumar AK, et al.: Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis 2004, 38:280-283.
8. Bushen O, Davenport J, Lima A, et al.: Diarrhea and reduced levels of antiretroviral drugs: improvement with glutamine or alanyl-glutamine in a randomized controlled trial in northeast Brazil. Clin Infect Dis 2004, 38:1764-1770.
9. Smith P, Janoff E: Gastrointestinal infections in HIV-1 disease. In Infections of the Gastrointestinal Tract, edn 2. Edited by Blaser MJ, Smith PD, Ravdin JI, et al. Philadelphia: Lippincott Williams & Wilkins; 2002:415-443.
10. Keating J, Bjarnason I, Somasundaram S, et al.: Intestinal absorptive capacity, intestinal permeability and jejunal histology in HTV and their relation to diarrhoea. Gut 1995, 37:623-629.
11. Sharpstone D, Neild P, Crane R, et al.: Small intestinal transit, absorption, and permeability in patients with AIDS with and without diarrhoea. Gut 1999, 45:70-76.
12. Pernet P, Vittecoq D, Kodjo A, et al.: Intestinal absorption and permeability in human immunodeficiency virus-infected patients. Scand J Gastroenterol 1999, 34:29-34.
13. Bini EJ, Cohen J: Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected patients with chronic diarrhea. Am J Gastroenterol 1999, 94:3553-3559.
14. Cohen J, West A, Bini E: Infectious diarrhea in human immunodeficiency virus [review]. Gastroenterol Clin North Am 2001, 30:637-664.
15. Kelly P, Lungu F, Keane E, et al.: Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial. Br Med J 1996, 312:1187-1191.
16. Kearney DJ, Steuerwald M, Koch J, Cello JP: A prospective study of endoscopy in HIV-associated diarrhea. Am J Gastroenterol 1999, 94:596-602.
17. Dieterich DT, Rahmin M: Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991, 4(Suppl 1):S29-S35.
18. Blanshard C, Francis N, Gazzard BG: Investigation of chronic diarrhoea in acquired immunodeficiency syndrome. A prospective study of 155 patients. Gut 1996, 39:824-832.
19. Cranston RD, Anton PA, McGowan IM: Gastrointestinal mucosal biopsy in HIV disease and AIDS [review]. Gastrointest Endosc Clin N Am 2000, 10:637-667, vi.
20. Anastasi JK, Capili B: HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations. Am J Infect Control 2000, 28:262-266.
21. Germani Y, Minssart P, Vohito M, et al.: Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. Am J Trop Med Hyg 1998, 59:1008-1014.
22. Carr A, Marriott D, Field A, et al.: Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998, 351:256-261.
23. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 2004, 53(RR-15):1-112.
24. Sherman DS, Fish DN: Management of protease inhibitor-associated diarrhea. Clin Infect Dis 2000, 30:908-914.
25. Bode H, Schmidt W, Schulzke JD, et al.: Effects of HIV protease inhibitors on barrier function in the human intestinal cell line HT-29/B6. Ann N Y Acad Sci 2000, 915:117-122.
26. Villamor E, Mbise R, Spiegelman D, et al.: Vitamin A supplements ameliorate the adverse effect of HIV-1, malaria, and diarrheal infections on child growth. Pediatrics 2002, 109:E6.
27. Fawzi WW, Msamanga GI, Wei R, et al.: Effect of providing vitamin supplements to human immunodeficiency virus-infected, lactating mothers on the child's morbidity and CD4+ cell counts. Clin Infect Dis 2003, 36:1053-1062.
28. Kelly P, Musonda R, Kafwembe E, et al.: Micronutrient supplementation in the AIDS diarrhoea-wasting syndrome in Zambia: a randomized controlled trial. AIDS 1999, 13:495-500.
29. Hayes C, Elliot E, Krales E, Downer G: Food and water safety for persons infected with human immunodeficiency virus. Clin Infect Dis 2003, 36:S106-S109.
30. Hoge C, Gambel J, Srijan A, Echeverria P: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998, 26:341-345.
31. Wanke C, Gerrior J, Blais V, et al.: Successful treatment of diarrheal disease associated with enteroaggregative Escherichia coli in adults infected with human immunodeficiency virus. J Infect Dis 1998, 178:1369-1372.
32. Mossoro C, Glaziou P, Yassibanda S, et al.: Chronic diarrhea, hemorrhagic colitis, and hemolytic-uremic syndrome associated with HEp-2 adherent Escherichia coli in adults infected with human immunodeficiency virus in Bangui, Central African Republic. J Clin Microbiol 2002, 40:3086-3088.
33. Verdier RI, Fitzgerald DW, Johnson WD, Jr, Pape JW: Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 2000, 132:885-888.
34. Fleming T, ed: Red Book, Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR; 2005.
35. Mermin J, Lule J, Ekwaru J, et al.: Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428-1434.
36. Drugs for parasitic infections. Med Lett Drugs Ther 2004, 46:1189.
37. Engberg J, Aarestrup FM, Taylor DE, et al.: Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001, 7:24-34.
38. Ward TT, Rimland D, Kauffman C, et al.: Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 1998, 27:1278-1285.
39. Dunne M, Fessel J, Kumar P, et al.: A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis 2000, 31:1245-1252.
40. Smith NH, Cron S, Valdez LM, et al.: Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis 1998, 178:900-903.
41. Kadappu KK, Nagaraja MV, Rao PV, Shastry BA: Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. J Postgrad Med 2002, 48:179-181.
42. Treating opportunistic infections among HIV-exposed and infected children. MMWR Morb Mortal Wkly Rep 2004, 53(RR-14):1-63.
43. Lu SS, Schwartz JM, Simon DM, Brandt LJ: Clostridium difficile-associated diarrhea in patients with HIV positivity and AIDS: a prospective controlled study. Am J Gastroenterol 1994, 89:1226-1229.
44. Pelaez T, Alcala L, Alonso R, et al.: Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46:1647-1650.
45. Rossignol JF, Hidalgo H, Feregrino M, et al.: A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998, 92:663-666.
46. Zulu I, Kelly P, Njobvu L, et al.: Nitazoxanide for persistent diarrhoea in Zambian acquired immune deficiency syndrome patients: a randomized-controlled trial. Aliment Pharmacol Ther 2005, 21:757-763.
47. Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005, 40:1173-1180.
48. Giacometti A, Cirioni O, Barchiesi F, et al.: Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 2000, 45:453-456.
49. White AC, Jr, Chappell CL, Hayat CS, et al.: Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994, 170:419-424.
50. Hewitt RG, Yiannoutsos CT, Higgs ES, et al.: Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 2000, 31:1084-1092.
51. Zulu I, Veitch A, Sianongo S, et al.: Albendazole chemotherapy for AIDS-related diarrhoea in Zambia - clinical, parasitological and mucosal responses. Aliment Pharmacol Ther 2002, 16:595-601.
52. Dieterich DT, Lew EA, Kotler DP, et al.: Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994, 169:178-183.
53. Molina JM, Chastang C, Goguel J, et al.: Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998, 177:1373-1377.
54. Conteas C, Berlin G, Ash L, Pruthi J: Therapy for human gastrointestinal microsporidiosis. Am J Trop Med Hyg 2000, 63:121-127.
55. Molina J, Tourneur M, Sarfati C, et al.: Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 2002, 346:1963-1969.
56. Conteas C, Berlin O, Speck C, et al.: Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998, 58:555-558.
57. Dieterich DT, Kotler DP, Busch DE et al.: Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 1993, 167:278-282.
58. Blanshard C, Benhamou Y, Dohin E, et al.: Treatment of AIDS-associated gastrointestinal cytomegalovirus infection with foscarnet and ganciclovir: a randomized comparison. J Infect Dis 1995, 172:622-628.
59. Squires KE: Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. AIDS 1996, 10(Suppl 4):S13-S18.
60. Martin DF, Sierra-Madero J, Walmsley S, et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002, 346:1119-1126.
61. Jabs DA, Enger C, Forman M, Dunn JP: Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother 1998, 42:2240-2244.
62. Jabs DA, Enger C, Dunn JP, Forman M: Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998, 177:770-773.
63. Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, et al.: Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 1994, 8:1563-1567.
64. Simon DM, Cello JP, Valenzuela J, et al.: Multicenter trial of octreotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhea. Gastroenterology 1995, 108:1753-1760.
65. Palmer K, Corbett C, Holdsworth C: Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology 1980, 79:1272-1275.
66. Didier E: Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob Agents Chemother 1997, 41:1541-1546.
67. Coyle C, Kent M, Tanowitz H, et al.: TNP-470 is an effective antimicrosporidial agent. J Infect Dis 1998, 177:515-518.
68. Sobottka I, Bartscht K, Schafer P, et al.: In vitro activity of polyoxin D and nikkomycin Z against Encephalitozoon cuniculi. Parasitol Res 2002, 88:451-453.
69. Bacchi C, Weiss L, Lane S, et al.: Novel synthetic polyamines are effective in the treatment of experimental microsporidiosis, an opportunistic AIDS-associated infection. Antimicrob Agents Chemother 2002, 46:55-61.
70. Price D, Schmid M, Ong E, et al.: Pancreatic exocrine insufficiency in HIV-positive patients. HIV Med 2005, 6:33-36.
71. Wignot TM, Stewart RP, Schray KJ, et al.: In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes. Pharm Res 2004, 21:420-427.
72. Holodniy M, Koch J, Mistal M, et al.: A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am J Gastroenterol 1999, 94:3267-3273.
73. Huffman F, Walgren M: L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals. HIV Clin Trials 2003, 4:324-329.
74. Jensen-Fangel S, Justesen US, Black FT, et al.: The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients. HIV Med 2003, 4:48-52.